Short answer
MANNKIND CORP (MNKD) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $109M (up 42.9% year over year) with net income of −$19M.
Q2 2026 key financials · XBRL
- Revenue
- $109M
- +42.9% YoY · +21.3% QoQ
- Net income
- −$19M
- −2949.1% YoY · −14.5% QoQ
- Operating margin
- -0.3%
- EPS (diluted)
- −$0.07
- −40.0% QoQ
Source: XBRL data from the MANNKIND CORP (MNKD) Q2 2026 10-Q on SEC EDGAR. USD.
MANNKIND CORP Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $109.4M, up 43% YoY from $76.5M, driven by commercial sales and collaborations
- Commercial gross margin 66% vs 79% YoY, with Furoscix carrying lower margins than Afrezza
- Best product Furoscix: $22.2M net revenue; worst V-Go: net revenue down $1.4M, or 33% YoY
- GAAP net loss $19.0M vs $0.7M net income YoY; non-GAAP net loss $2.7M vs $13.9M income
- New $325.0M term loans increased interest expense; management expects liquidity sources to meet needs over the next 12 months
Risk Factors
- Newly emphasized partner-concentration risk: United Therapeutics’ Tresmi plans and ralinepag DPI NDA could reduce Tyvaso DPI emphasis and royalties
- Most materially updated trade risk: tariffs may raise costs while fixed customer contracts delay pass-through up to 36 months
- Regulatory compliance risk: FDA inspection findings could require onerous corrective actions and suspend manufacturing
- Operational risk: V-Go depends on Chinese contract manufacturers despite limited duty-free treatment under HTSUS
- Financial risk: scPharma acquisition increased net debt, liquidity pressure, interest expense, leverage and debt-service requirements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MANNKIND CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.